Nanjing Pharmaceutical
Nanjing Pharmaceutical, also known as Nanjing Pharmaceutical Company Limited, is a prominent player in the pharmaceutical industry, headquartered in Nanjing, China. Established in 1995, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms.
With a strong operational presence across Asia and expanding into international markets, Nanjing Pharmaceutical is recognised for its commitment to quality and innovation. The company’s core offerings include generic medications and specialty pharmaceuticals, distinguished by their rigorous adherence to international standards and advanced production techniques.
Nanjing Pharmaceutical has achieved notable milestones, positioning itself as a trusted name in the industry, with a focus on enhancing healthcare solutions globally. Its dedication to research and development continues to drive its success in a competitive market.
-18 vs industry average
Nanjing Pharmaceutical’s score of 20 is lower than 35% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Nanjing Pharmaceutical?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2026
Reported emissions
Scope 3 accounts for ••• of total emissions.
Nanjing Pharmaceutical's reported carbon emissions
In 2023, Nanjing Pharmaceutical reported total carbon emissions of approximately 67.6 million kg CO2e. This figure comprises 4.996 million kg CO2e from Scope 1 emissions and about 62.6 million kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data. Comparatively, emissions in 2022 were approximately 69.3 million kg CO2e, with Scope 1 emissions at 5.280 million kg CO2e and Scope 2 emissions at about 63.9 million kg CO2e. In 2021, total emissions were around 60.5 million kg CO2e, with Scope 1 at 4.513 million kg CO2e and Scope 2 at approximately 56.0 million kg CO2e. Despite these figures, Nanjing Pharmaceutical has not set any specific reduction targets or climate pledges, indicating a potential area for improvement in their climate commitments. The data is not cascaded from any parent organization, and all emissions data is sourced directly from Nanjing Pharmaceutical Company Limited.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Nanjing Pharmaceutical’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Nanjing Pharmaceutical yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Nanjing Pharmaceutical
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project